Cohance Lifesciences Limited

Cohance Lifesciences Receives USFDA Warning Letter for Hyderabad Facility

Cohance Lifesciences received a USFDA warning letter for its Hyderabad FDF Unit-I facility after an inspection from August 4-12, 2025. The facility was classified as OAI. US revenues from this unit were less than 2% of FY25 consolidated revenues, with EBITDA contribution below 1%. The company is taking corrective actions.

Cohance Lifesciences Receives USFDA Warning Letter for Nacharam Facility

Cohance Lifesciences received a USFDA Warning Letter for its Nacharam, Hyderabad facility. The company stated that US revenues from this facility contributed less than 2% of consolidated revenues in FY2025, with EBITDA contribution below 1%. Cohance is committed to resolving the issues with the USFDA.

Cohance Lifesciences: Company Secretary and Compliance Officer Resigns

Mr. Kundan Kumar Jha has resigned as Company Secretary, Compliance Officer, and Head - Legal of Cohance Lifesciences Limited. His resignation is effective February 4, 2026, as he seeks new professional opportunities. He submitted his resignation on November 7, 2025.

Cohance Lifesciences Appoints Mr. Himanshu Agarwal as Whole-time Director

Cohance Lifesciences Limited announced the appointment of Mr. Himanshu Agarwal as Whole-time Director. The resolution was passed via postal ballot with 96.862% of votes in favour. The e-voting period concluded on January 22, 2026.

Cohance Lifesciences Schedules Q3 & 9MFY26 Results Conference Call for Feb 12, 2026

Cohance Lifesciences will host an investor and analyst conference call on February 12, 2026, at 6:15 PM IST to discuss its Q3 & 9MFY26 Un-audited Financial Results. The call will include a management discussion and Q&A session. Dial-in details and pre-registration information are provided.

Cohance Lifesciences Appoints Mr. Sunil Kumar Singh as Senior Management Personnel

Cohance Lifesciences appointed Mr. Sunil Kumar Singh as Senior Management Personnel, effective January 19, 2026. Mr. Singh joined as Chief Quality Officer in December 2025 and brings over 35 years of pharmaceutical quality leadership experience from companies like Dr. Reddy's Laboratories.

Cohance Lifesciences Grants 3,89,668 Stock Options to Employees

Cohance Lifesciences granted 3,89,668 stock options to employees under ESOP 2023 on January 17, 2026. This includes 2,18,077 options related to an amalgamation scheme approved on March 27, 2025. Some options vest starting one year from grant, while others vest on April 1, 2026.

Cohance Lifesciences Files SEBI Compliance Certificate for Q3 FY26

Cohance Lifesciences Limited filed a certificate under SEBI regulations for the quarter ended December 31, 2025. The certificate confirms dematerialization/rematerialization of securities, as furnished to stock exchanges by the Registrar and Share Transfer Agents, KFin Technologies Limited.

Cohance Lifesciences to consider Q3 FY26 results on Feb 12, 2026; trading window closed

Cohance Lifesciences will hold a Board Meeting on February 12, 2026, to approve the Unaudited Financial Results for the quarter and nine-months ending December 31, 2025. The trading window will be closed from January 1, 2026, to February 14, 2026.

Cohance Lifesciences Announces Special Window for Re-lodgement of Physical Share Transfer Requests

Cohance Lifesciences opens a special window from July 7, 2025, to January 6, 2026, for re-lodging physical share transfer requests rejected before April 1, 2019. Shareholders should contact KFin Technologies Limited for assistance. Advertisements were published on December 27, 2025.

Cohance Lifesciences Announces Newspaper Publication for Postal Ballot Notice

Cohance Lifesciences Limited has published a Notice of Postal Ballot for members to approve the appointment of Mr. Himanshu Agarwal as a Whole-time Director. E-voting commences on December 24, 2025, and ends on January 22, 2026. Results will be announced by January 23, 2026.

Cohance Lifesciences Seeks Member Approval for Himanshu Agarwal's Whole-Time Director Appointment

Cohance Lifesciences is seeking member approval to appoint Mr. Himanshu Agarwal as Whole-Time Director and CFO for five years from October 29, 2025. E-voting is from December 24, 2025, to January 22, 2026. His remuneration includes fixed compensation of ₹3 Crores and variable compensation of ₹60 Lakhs for FY26, increasing from April 1, 2026.

Cohance Lifesciences Resubmits Q2 FY26 Unaudited Financial Results

Cohance Lifesciences Limited re-submitted its Q2 FY26 unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, with no changes from the November 12, 2025 submission. Standalone revenue was ₹497.79 crore and net profit ₹94.19 crore. Consolidated revenue was ₹555.57 crore and net profit ₹66.39 crore.

Cohance Lifesciences Changes Website Address Post Name Change

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, has officially changed its website address from www.suvenpharm.com to www.cohance.com. This update follows the company's recent name change and has been communicated to the stock exchanges.

Cohance Lifesciences to Hold Roadshow with Analysts/Investors on Dec 17

Cohance Lifesciences Limited will host a roadshow for analysts and institutional investors in Hyderabad on December 17, 2025. The event will be a group meeting, and no unpublished price-sensitive information will be disclosed.

Cohance Lifesciences Appoints Senior Management Personnel

Cohance Lifesciences appointed Mr. Gunjan Singh as Business Head – API plus, Mr. Amrit Singh as Head – Specialty Chemicals and Mr. Ravinatha Shetty as Platform Chief Operating Officer, effective December 5, 2025.

Credit Rating Assigned to Cohance Lifesciences Limited

India Ratings assigns IND AA/Stable/IND A1+ ratings to Cohance Lifesciences Limited's bank loan facilities of ₹685 crore.

Cohance Lifesciences grants 80,15,626 stock options under ESOP 2023

Cohance Lifesciences grants 80,15,626 stock options to eligible employees under ESOP 2023, vesting over 1-10 years and exercisable within 3 years post-vesting.

Cohance Lifesciences to Invest USD 10 Million in NJ Bio Inc.

Cohance Lifesciences will invest up to USD 10 million (₹83 crore approx.) in NJ Bio Inc. to support growth initiatives including capex.

Cohance Lifesciences Announces Participation in Elara India Conference

Cohance Lifesciences to attend Elara India Conference in Singapore and Hong Kong on December 3-4, 2025, for group and one-on-one meetings. No UPSI to be shared.

Cohance Lifesciences to attend Citigroup Plant Visit & Roadshow

Cohance Lifesciences Limited announced that its management will attend the Citigroup Plant Visit & Roadshow in Hyderabad on November 27, 2025. No unpublished price-sensitive information will be shared.

Cohance Lifesciences Announces Earnings Conference Call Transcript

Cohance Lifesciences releases transcript of earnings call for quarter and half year ended September 30, 2025, highlighting U.S. regulatory approval, customer engagement, and financial performance with revised FY26 guidance.

Newspaper Publication of Unaudited Financial Results

Cohance Lifesciences Limited announced the publication of unaudited financial results for the quarter and half year ended September 30, 2025, in Business Standard and Lokmat on November 14, 2025.

Audio Recording of Conference Call for Quarter Ended September 30, 2025

Cohance Lifesciences Limited has uploaded the audio recording of the conference call for the quarter and half year ended September 30, 2025, on its website. The call was held on November 12, 2025.

Cohance Lifesciences Reports Q2FY26 Results: Strategic Investments Amidst Near-Term Challenges

Cohance Lifesciences reported Q2FY26 results with revenue and PAT declines due to destocking and plant shutdown. The company highlighted strategic investments, capability expansion, and a positive long-term growth outlook.

Cohance Lifesciences reports mixed Q2/H1 FY26 results, revenue down 8% YoY in Q2; reaffirms 2030 targets

Cohance Lifesciences reported unaudited Q2 and H1 FY26 financial results. Q2 revenue declined 8% YoY, but gross margins improved. The company reaffirmed its USD 1 billion revenue target by 2030, despite near-term headwinds.

Cohance Lifesciences to host Q2 & H1 FY26 earnings conference call on November 12, 2025

Cohance Lifesciences will host a conference call on November 12, 2025, at 7:00 p.m. IST to discuss its unaudited Q2 & H1 FY26 financial results, which will be considered on the same day.

Cohance Lifesciences Announces Participation in Analyst/Institutional Investor Conferences

Cohance Lifesciences to attend Jefferies Roadshow (Nov 13-14), Avendus Spark Conference (Nov 18), JM Financial Conference (Nov 19) & Kotak Midcap Conference (Nov 20) in Mumbai.

Cohance Lifesciences Announces Leadership Changes and Strategic Updates

Cohance Lifesciences announces leadership changes, a revised organizational structure, and strategic updates, targeting US$ 1 billion (₹8,330 crore) revenue by 2030. Dr. Prasad a Raju steps down as Managing Director.

Cohance Lifesciences Uploads Audio Recording of Conference Call

Cohance Lifesciences Limited has uploaded the audio recording of its conference call held on October 28, 2025, to its website for investor access.

Cohance Lifesciences Schedules Concall on Oct 28 to Discuss Director Changes

Cohance Lifesciences scheduled a conference call for October 28, 2025, at 6:30 p.m. IST, to update investors and analysts on recent changes in the company's Directors.

Dr. V Prasada Raju resigns as MD; Mr. Himanshu Agarwal appointed Whole-time Director & CFO

Cohance Lifesciences announces the resignation of MD Dr. V Prasada Raju, effective October 28, 2025. Mr. Himanshu Agarwal, CFO, is appointed Whole-time Director and CFO from October 29, 2025, subject to shareholder approval.

COHANCE's FDF Unit-I receives USFDA 'Official Action Indicated' classification

Cohance Lifesciences' FDF Unit-I received an USFDA 'Official Action Indicated' classification with 6 observations. The company is remediating, stating minimal financial impact (less than 2% of US revenue) and normal operations continue.

Cohance Lifesciences submits SEBI Regulation 74(5) certificate for Q2 FY26

Cohance Lifesciences submitted the Regulation 74(5) certificate for the quarter ended September 30, 2025, confirming dematerialized/rematerialized securities details to stock exchanges.

Cohance Lifesciences informs shareholders about 'Saksham Niveshak' campaign.

Cohance Lifesciences: Proceedings and Voting Results of 7th AGM

Clarification on USFDA Inspection News

Cohance Lifesciences to attend JP Morgan Conference and Roadshow

Cohance Lifesciences Promoter Sells ₹3,093.81 Crore Shares for Debt Repayment

Cohance Lifesciences' API Unit-1 clears USFDA inspection with zero observations

Cohance Lifesciences to Hold 7th AGM on Sep 19, 2025; Annual Report for FY25 Available

Dr. V Prasada Raju, MD, sells 6,00,000 shares of Cohance Lifesciences

Cohance Lifesciences announces 7th AGM and e-voting information

CRISIL Upgrades Cohance Lifesciences' Long-Term Rating to 'AA-/Positive'

Cohance Lifesciences to Hold 7th AGM on September 19, 2025; Agenda Includes Financials & Director Matters

Cohance Lifesciences Q1 FY26 Earnings: CDMO grows, expands capacity

COHANCE provides Corporate Guarantee for NJ Bio Inc.

Cohance Lifesciences Appoints Yann D'Herve as New CDMO Business CEO

Cohance Lifesciences to Host Q1FY26 Results Conference Call on August 13, 2025